Dimension Therapeutics Reports Recent Corporate Progress and Full Year 2015 Financial Results
- Treated first patients in phase I/II clinical study of DTX101 for hemophilia B - - Expect to file an IND and initiate dosing for DTX301 for OTC deficiency in second half 2016 - - Selected candidate for GSDIa and expect to file an IND in second half 2016 …